重组人白细胞介素-2辅助治疗复治肺结核观察  

Clinical Study on the Effects of rhIL-2 on the Adjuvant Treatment of Reactivation Tuberculosis

作　　者：秦超[1] 刘俊英[1] 姚宜春[1] 苑松林[1] 

机构地区：[1]天津市海河医院结核科,300350

出　　处：《天津医药》2005年第6期342-344,共3页Tianjin Medical Journal

摘　　要：目的:评价重组人白细胞介素-2(rhIL-2)对复治肺结核的辅助治疗效果。方法:将43例复治肺结核患者随机分为观察组23例,对照组20例。2组抗结核治疗方案一致,观察组另外应用rHIL-2,2×105U皮下注射60d。结果:2个月痰菌阴转率观察组优于对照组(P<0.05),7个月时CD4和CD4/CD8比值均明显增高,与对照组比较差别有统计学意义(P<0.05)。白细胞介素-2可溶性受体(sIL-2R)观察组明显下降,与对照组比较差别有统计学意义(P<0.05)。结论:rhIL-2辅助治疗复治肺结核有效。Objective: To study the effects of rhIL-2 on the adjuvent treatment of reactivation tuberculosis. Methods: Forty-three patients with reactivation tuberculosis were randomly divided into trial group (23 cases) and control group (20 cases). 2 × 105 units rhIL-2 were injected subcutaneously for 60 days in trial group besides the same antitubercular agents administrated in both two groups. Results: The negative rate of sputum in trial group was higher than that in control group after two months (P < 0.05). The CD4 and CD4/CD8 ratio in trial group increased significantly 7 months after the treatment and it was significantly different compared with control group (P < 0.05). The level of serum receptor sIL-2R in trial group decreased significantly and it was significantly different compared with control group (P < 0.05). Conclusion: rhIL-2 is effective as adjuvent treatment of reactivation tuberculosis.

关 键 词：复治肺结核 重组人白细胞介素-2 辅助治疗 CD4/CD8比值 RHIL-2 肺结核患者 痰菌阴转率 可溶性受体 观察组 对照组 治疗效果 治疗方案 皮下注射 统计学 抗结核 差别 

分 类 号：R521[医药卫生—内科学] R512.91[医药卫生—临床医学]